Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment…
Pharmaceuticals, Biotechnology and Life Sciences
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment…
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and…
Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024+4.8% at actual rates impacted…
WALTHAM, Mass., Jan. 19, 2026 (GLOBE NEWSWIRE) — BVI, a global leader in the ophthalmic device market, announced today the…
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”),…
KUALA LUMPUR, Malaysia, Jan. 19, 2026 (GLOBE NEWSWIRE) — CUKTECH has officially announced the launch of its flagship product, the…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
CHAPEL-EN-LE-FRITH, United Kingdom, Jan. 19, 2026 (GLOBE NEWSWIRE) — Concept Life Sciences, a leading global contract research organization (CRO) specialising…
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on…
Approval Label May Include Opioid ReductionNEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in…